Independent fund research. Built on SEC filings.

How we research funds

Fund comparison

IBB vs. SHPAX: which is better?

Bottom line

IBB vs SHPAX: the short answer

IBB (iShares Biotechnology ETF) and SHPAX (Health & Biotechnology Portfolio) are quite different portfolios: only about 24% of their top holdings (by weight) are shared.

But IBB is far broader, holding 254 positions to 29 for SHPAX, so beyond the top names it adds exposure SHPAX doesn't have.

IBB is cheaper at 0.44% vs 3% — a difference of $256 a year per $10,000 invested.

Over five years, SHPAX returned +3.1% a year vs +2.5% for IBB (reporting dates differ).

SHPAX has a front-end sales load of up to 5.75%; the other does not.

Updated Nov 19, 2026

IBB vs SHPAX side by side

IBBSHPAX
TypeETFMutual fund
Fund familyiSharesSaratoga Advantage
CategoryTechnology SectorTechnology Sector
Expense ratio0.44%3%
Annual cost per $10k$44$300
10-yr cost on $10k (prospectus)$555$3,702
Max front loadNone5.75%
12b-1 fee0%—
1-yr return+28.0%−5.5%
5-yr return (annualized)+2.5%+3.1%
10-yr return (annualized)+4.4%+4.1%
Best quarter+26.8%+15.0%
Worst quarter−22.9%−13.0%
Net assets (fund)$5.9B$10.5M
Number of holdings25429
Portfolio turnover27%22%
Returns as ofDec 31, 2025Dec 31, 2024

Source: SEC Form N-PORT and fund prospectuses

Year-by-year returns

YearIBBSHPAXDifference
2024−2.4%+0.3%−2.7%
2023+3.6%−0.4%+4.0%
2022−13.6%+2.0%−15.6%
2021+1.0%+16.7%−15.7%
2020+25.9%+3.6%+22.3%
2019+24.8%+16.2%+8.6%
2018−9.1%−5.5%−3.7%
2017+21.2%+12.0%+9.3%
2016−21.5%−2.0%−19.6%
2015+11.5%+6.9%+4.6%

Source: Fund prospectus bar charts

Holdings overlap

8 of IBB's top 25 holdings also appear in SHPAX's top 25.

Shared top holdings
HoldingIBBSHPAX
Vertex Pharmaceuticals, Inc.7.66%3.36%
Gilead Sciences, Inc.7.52%3.94%
Amgen, Inc.7.50%5.04%
Regeneron Pharmaceuticals, Inc.5.70%3.93%
United Therapeutics Corp.1.82%6.17%
Incyte Corp.1.62%2.89%
Medpace Holdings, Inc.1.16%3.37%
Exelixis, Inc.1.07%4.55%

Source: SEC Form N-PORT

IBB top 10

  1. BlackRock Funds III — 13.18%
  2. Vertex Pharmaceuticals, Inc. — 7.66%
  3. Gilead Sciences, Inc. — 7.52%
  4. Amgen, Inc. — 7.50%
  5. Regeneron Pharmaceuticals, Inc. — 5.70%
  6. Alnylam Pharmaceuticals, Inc. — 5.68%
  7. IQVIA Holdings, Inc. — 3.18%
  8. Argenx SE — 3.15%
  9. Insmed, Inc. — 2.95%
  10. Mettler-Toledo International, Inc. — 2.49%

SHPAX top 10

  1. Cardinal Health Inc — 6.44%
  2. Jazz Pharmaceuticals Plc — 6.19%
  3. United Therapeutics Corp — 6.17%
  4. Amgen Inc — 5.04%
  5. Mckesson Corp — 4.90%
  6. Lantheus Holdings Inc — 4.64%
  7. Exelixis Inc — 4.55%
  8. Novartis Ag — 4.50%
  9. Cencora Inc — 4.33%
  10. Gilead Sciences Inc — 3.94%

FAQ

What is the difference between IBB and SHPAX?
IBB (iShares Biotechnology ETF) and SHPAX (Health & Biotechnology Portfolio) are quite different portfolios: only about 24% of their top holdings (by weight) are shared. But IBB is far broader, holding 254 positions to 29 for SHPAX, so beyond the top names it adds exposure SHPAX doesn't have.
Which is cheaper, IBB or SHPAX?
IBB has the lower expense ratio (0.44%).
Should I own both IBB and SHPAX?
Because their portfolios differ, owning both can add diversification — check how they fit your overall allocation.

Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.